Enterophar is commonly used to help manage symptoms associated with certain gastrointestinal conditions, providing supportive therapeutic benefit. This medication is generally applied in clinical settings that involve acute or disruptive symptom patterns, and is relevant in situations where symptoms are linked to an irritative state.

Therapeutic Focus and Benefit

The medication may assist with managing symptomatic episodes in conditions involving acute bacterial diarrhea, Traveler's Diarrhea, and certain protozoal infections such as Giardiasis. It plays a role in managing symptom clusters that may create noticeable physiological strain, including frequent loose stools, abdominal cramping, and generalized gastrointestinal distress. Applied during phases when symptoms become more noticeable, it supports patients during difficult episodes.

“This approach helps address symptoms related to inflammatory or irritative states in the gut, which contributes to improved day-to-day comfort during symptomatic periods.”

Its application is aligned with contexts where short-term symptomatic assistance is needed, providing support that helps ease the overall symptom burden and assists with maintaining functional stability.

---

Quick Fact: Support for Diarrhea and Cramping Symptoms This medicine is commonly used to help manage symptoms related to physical discomfort arising from intestinal infection, specifically watery stools and associated abdominal pain.

Regulatory References

1. National Cancer Institute Drug Dictionary

Who can and cannot use Enterophar?

This section defines population eligibility for Enterophar (Furazolidone) based strictly on official regulatory documentation.

Age Group	Eligibility Status
Infants under 1 month	Contraindicated / Not Recommended (due to risk of hemolytic anemia)
Children 1 month and older	Permitted for use
Adults	Permitted for use
Older Adults (Geriatric)	Use not specifically compared in regulatory data

Absolute Contraindications

The medicine must not be administered to patients with a known prior sensitivity (allergy) to Furazolidone or to individuals diagnosed with Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency, as this deficiency carries a risk of hemolysis [Source 1.2, 1.5, 2.6].

Conditional Use and Restrictions

• Pregnancy and Childbearing Age: Safety has not been established; use is directed with caution [Source 1.3].
• Breastfeeding/Lactation: Safety has not been established because the drug's distribution into breast milk has not been determined [Source 1.3].
• Dietary Restrictions: Consumption of Tyramine-containing foods and alcoholic beverages is contraindicated during therapy and for four days after stopping the medicine [Source 1.1, 1.2, 1.3].

The interaction profile for Enterophar (Furazolidone) is governed by its documented property as a Monoamine Oxidase Inhibitor (MAOI). This MAOI activity dictates specific restrictions concerning co-administered medicinal products and dietary intake, as mandated by official regulatory bodies.

Interaction Category	Restrictions and Official Outcomes
Contraindicated Combinations	Co-administration with other MAO Inhibitors and Indirect-acting Sympathomimetic Amines (e.g., phenylephrine) is formally restricted due to the serious risk of a hypertensive crisis.
Pharmacodynamic Risks	Combining the drug with Serotonergic Agents (e.g., Tricyclic Antidepressants) carries a documented risk of Serotonin Syndrome. Additive Central Nervous System (CNS) depression may occur with other CNS depressants.
Dietary & Substance Avoidance	Consumption of alcohol (ethanol) is restricted during therapy and for a mandatory period of 4 days after discontinuation due to the potential for a disulfiram-like reaction. Tyramine-containing foods must be strictly avoided during treatment and for 2 weeks following discontinuation to mitigate the risk of severe pressor amine toxicity.
Population Considerations	The medication is contraindicated in infants under 1 month of age. A risk of mild, reversible intravascular hemolysis is noted in patients with Glucose-6-phosphate dehydrogenase (G-6-PD) deficiency.

The drug's official interaction structure is defined by non-co-administration constraints and required post-treatment avoidance periods. These constraints are required to manage the potential for significant exposure-altering and pharmacodynamic interactions stemming from the MAOI effect, as detailed in regulatory prescribing information.

The function of Enterophar (Furazolidone) is based on two distinct pharmacodynamic mechanisms: the active destruction of pathogens and the systemic effect on host enzymes.

Bioactivation and Lethal Multi-Target Damage

The primary pharmacodynamic action involves bioactivation initiated by the pathogen's own nitroreductase enzymes, which convert the drug into highly toxic intermediate compounds exclusively within the microbial cell. These reactive chemicals immediately and irreversibly damage the pathogen's DNA while simultaneously inactivating multiple metabolic enzymes necessary for survival. This sequence constitutes a lethal, bactericidal and antiprotozoal mechanism; its direct molecular consequences result in microbial cell death and loss of viability.

Systemic Enzyme Inhibition and Mechanistic Constraints

A secondary, non-antimicrobial effect is the irreversible inhibition of host Monoamine Oxidase (MAO) enzymes throughout the body, altering the natural catabolism of biogenic amines like norepinephrine. This systemic effect on neurotransmitter metabolism is a critical consideration in the drug’s overall profile. Efficacy, however, is constrained because the primary lethal mechanism is dependent on the low-oxygen environment required for optimal microbial enzyme activity and is limited by pathogen mutations that confer resistance to the activation process.

The administration of Enterophar (Furazolidone) is conducted via the oral route, supplied in a 100 mg tablet and a liquid oral suspension.

The dosing schedule for adults is typically a 100 mg single dose, taken four times daily (q.i.d.), to achieve a total daily amount of 400 mg. This frequency is structured to ensure administration at evenly spaced intervals throughout the day. Timing in relation to meals permits the medicine to be taken with food or milk, a condition specified to mitigate potential irritation of the gastrointestinal tract.

When utilizing the liquid preparation, the oral suspension requires vigorous shaking prior to measurement, and the dose must be measured using a specially marked device for accuracy. Its use is generally not recommended for infants under one month of age. The missed-dose rules instruct that the next scheduled dose should not be doubled. The complete course duration, which may range from five to ten days, must be fully observed, representing a critical special procedural condition of its use.

Research evidence / Overview of Studies for Enterophar (Furazolidone)

---

Research Structure for Protozoal Intestinal Infection (Giardiasis)

Research examined the active ingredient in patients with the intestinal infection known as Giardiasis. Studies include Randomized Controlled Trials (RCTs) that evaluated two main outcomes: a measurement of parasitological clearance (confirmed absence of the parasite after treatment) and measuring outcomes related to physical discomfort. Findings describe patterns observed in the studies related to clearance, with measured rates being reported across different treatment durations in both children and adults.

Long-term effects are not fully established. Follow-up durations were limited, often assessing clearance only a few weeks post-treatment. Data for certain groups, such as older adults, remain insufficient, meaning the research mainly applies only to the populations specifically studied.

---

Research Structure for Acute Bacterial Diarrhea

The active ingredient was studied for its role in managing acute infectious diarrhea and colitis. The research explored short-term symptom changes and monitored the measurement of bacterial pathogen clearance and outcomes related to physical discomfort. Clinical data show patterns related to changes measured during the study period (typically 5 to 7 days). Older observational data research describes the spectrum of susceptible organisms.

Certainty remains low for general use in acute bacterial diarrhea because there is a lack of recent, large-scale RCTs that directly compare this agent with current standard therapies. The research has focused on the short-term measurement of pathogen outcomes; limited information exists for long-term outcomes concerning bowel function.

---

Research Structure for Helicobacter pylori Eradication

High-level evidence, including Systematic Reviews and Meta-Analyses, supports the use of the active ingredient as a component of multi-drug combination therapy for eradicating the H. pylori bacteria. Research monitored the pathogen eradication rate as the primary outcome, assessed several weeks after the completion of the regimen.

The research predominantly focuses on the agent being a component of combination therapy, meaning the evidence base does not provide primary insight into its use as a stand-alone treatment.

Key Studies & References

1. Furazolidone treatment for Helicobacter Pylori infection: A systematic review and meta-analysis
2. Five v ten days' therapy with furazolidone for giardiasis (Randomized Controlled Trial for children)
3. Giardiasis - Infectious Diseases (MSD Manual Professional Edition, listing furazolidone as rarely used)

Common questions about Enterophar (FAQ)

Q: How quickly should I expect to see an improvement after starting Enterophar?

Studies monitored short-term symptom changes during the typical 5- to 10-day treatment course. Official product information and clinical data do not specify a fixed number of days for an individual to feel an improvement. Regulatory warnings emphasize the importance of completing the full course as prescribed.

---

Q: How long does Enterophar usually stay in your system after the last dose?

Regulatory information indicates that the drug's effects can persist for a substantial period after the last dose. Official warnings require the avoidance of alcohol for at least 4 days and tyramine-containing foods for up to 2 weeks following the discontinuation of Enterophar. This required avoidance period is due to the drug's sustained effect on specific enzymes.

---

Q: Does Enterophar cause drowsiness or affect my ability to drive?

Official information lists dizziness and headache as common side effects. Furthermore, because Enterophar can interact with certain other medicines to cause Central Nervous System (CNS) depression, these effects may impair your ability to safely perform tasks requiring full concentration, such as driving or operating heavy machinery.

---

Q: Does Enterophar interact with common pain relievers like ibuprofen or acetaminophen?

Regulatory sources focus on major interaction categories, such as those involving other Monoamine Oxidase Inhibitors (MAOIs) or Serotonergic Agents. There is no major interaction warning against taking Enterophar with acetaminophen (paracetamol) or ibuprofen. However, it is recommended that a healthcare professional review the full medication list for potential interactions, especially with medicines that affect the central nervous system.

---

Q: Is Enterophar transferred into breast milk?

Studies have not determined whether the active ingredient in Enterophar is distributed into breast milk. Since its transfer into breast milk is not determined, the safety of using Enterophar during breastfeeding has not been established in regulatory documents.

---

Q: Are there specific considerations for elderly patients taking Enterophar?

Official regulatory data on Enterophar states that studies have not specifically compared the use of this medicine in older adults (geriatric population) versus younger adults. The data available for this specific age group is noted in regulatory materials as being insufficient for direct comparison.

---

Q: Does Enterophar interact with caffeine or certain energy drinks?

Enterophar is a type of Monoamine Oxidase Inhibitor (MAOI). MAOIs can interact with certain stimulants, specifically indirectly-acting sympathomimetic amines, which are strictly contraindicated due to the risk of a hypertensive crisis (a severe spike in blood pressure). The MAOI property necessitates caution when combining it with other stimulant agents.

---

Q: Why do some people experience a 'Disulfiram-like reaction' with Enterophar and alcohol?

The 'disulfiram-like reaction' is a physiological response that occurs when alcohol is consumed while taking Enterophar. The drug interferes with the body's normal process of breaking down alcohol by inhibiting the enzyme that clears a toxic metabolite called acetaldehyde. Because of this risk, official regulations require the strict avoidance of alcohol during treatment and for a period afterward.

---

Q: Can I crush the Enterophar tablet, or must I swallow it whole?

Regulatory documents indicate that the tablet form of the medicine is often scored (has a line to facilitate splitting), and the dosage may be crushed for children and mixed with an edible medium like corn syrup. This information is intended to facilitate the administration of the prescribed dose.

---

Q: Does Enterophar affect blood sugar levels, especially in non-diabetics?

While there is no general warning that Enterophar affects blood sugar in healthy individuals, official interaction data suggests that the drug may increase the glucose-lowering effects of certain medications used to treat diabetes. This highlights the need to monitor blood glucose when Enterophar is used alongside these medications.

---

Q: Can Enterophar affect the results of any common lab tests?

Yes, regulatory documents note a common, harmless side effect of the medicine is causing a brown or dark yellow discoloration of the urine. This visual change is a known factor that may need to be considered when interpreting certain lab tests conducted on urine samples.

---

Q: Is Enterophar a common treatment option in all parts of the world?

Enterophar (Furazolidone) has been discontinued or its use severely restricted in some countries, such as the United States and parts of the European Union. However, official sources note that the drug remains available and is actively utilized in other global settings, particularly for its efficacy and cost-effectiveness in certain infectious diseases.

---

Q: What is the risk of developing resistance to Enterophar over time?

The mechanism of action of Enterophar is known to target microbial enzymes. However, studies on certain bacteria like Salmonella have observed cases of acquired resistance. This suggests that while resistance may be less common, it remains a biological possibility that is monitored in research settings.

---

Q: Does Enterophar affect gut flora balance?

As an oral antimicrobial agent (an antibiotic and antiprotozoal drug), Enterophar's core function is to eliminate pathogens in the gut. It targets bacteria in the digestive tract, and it is recognized that such medicines may cause an alteration in the balance of the natural intestinal flora (gut bacteria).

---

Q: Are there any specific monitoring tests required while on a course of Enterophar?

Official warnings stipulate that patients who have Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency must be observed closely during therapy due to the risk of hemolysis (red blood cell destruction). The medicine is to be discontinued if signs of this condition are suspected.

---

Q: What are the signs of a serious allergic reaction to Enterophar?

Hypersensitivity reactions are listed as a less frequent adverse effect, manifesting as rash, fever, or a fall in blood pressure. Signs of a more severe allergic reaction (anaphylaxis) can include rapid swelling, difficulty breathing, or significant hypotension (low blood pressure). The occurrence of serious signs requires immediate medical review.

---

Q: What should I do if I accidentally take two doses of Enterophar too close together?

The rules for a missed dose state that the next scheduled dose should never be doubled. Any concerns regarding potential overdose or taking doses too close together should be immediately reviewed by a medical professional or a poison control center, as standard practice.

How to Store and Dispose of Enterophar

Enterophar (Furazolidone) must be stored strictly according to its regulatory labeling to maintain stability. The medicine must be kept at controlled room temperature and explicitly kept from freezing. Due to the light-sensitive nature of the active ingredient, the product must be stored in its closed container and protected from direct light, heat, and moisture.

All forms of this medicine must be kept out of the sight and reach of children.

Disposal must follow applicable laws and regulations. Unused or expired Enterophar should not be allowed to enter drains, sewer systems, or surface water. Regulatory instructions mandate disposal through approved channels, such as licensed chemical destruction or controlled incineration, to prevent environmental contamination.